SG Americas Securities LLC Raises Stake in Zoetis Inc. $ZTS

SG Americas Securities LLC increased its holdings in Zoetis Inc. (NYSE:ZTS) by 400.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 276,529 shares of the company’s stock after buying an additional 221,294 shares during the quarter. SG Americas Securities LLC owned about 0.06% of Zoetis worth $34,793,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Assenagon Asset Management S.A. boosted its holdings in shares of Zoetis by 134.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after acquiring an additional 935,432 shares during the last quarter. Seilern Investment Management Ltd increased its stake in shares of Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock worth $41,957,000 after acquiring an additional 261,155 shares during the period. M. Kulyk & Associates LLC raised its holdings in shares of Zoetis by 14.2% during the fourth quarter. M. Kulyk & Associates LLC now owns 21,223 shares of the company’s stock worth $2,670,000 after purchasing an additional 2,645 shares during the last quarter. NorthCrest Asset Manangement LLC lifted its position in Zoetis by 4.0% during the fourth quarter. NorthCrest Asset Manangement LLC now owns 32,127 shares of the company’s stock valued at $4,156,000 after purchasing an additional 1,234 shares during the period. Finally, Gryphon Financial Partners LLC lifted its position in Zoetis by 10.1% during the fourth quarter. Gryphon Financial Partners LLC now owns 2,650 shares of the company’s stock valued at $333,000 after purchasing an additional 244 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on ZTS shares. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. William Blair reissued an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Barclays began coverage on Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price on the stock. Weiss Ratings raised Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, March 12th. Finally, HSBC set a $140.00 price target on Zoetis in a research report on Wednesday, December 10th. Six analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, Zoetis presently has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Stock Up 0.6%

ZTS stock opened at $116.65 on Thursday. Zoetis Inc. has a one year low of $113.30 and a one year high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. The firm’s fifty day moving average is $123.79 and its 200 day moving average is $129.67. The firm has a market cap of $49.24 billion, a PE ratio of 19.38, a P/E/G ratio of 1.77 and a beta of 0.95.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same period in the prior year, the company posted $1.40 EPS. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s dividend payout ratio is currently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.